| Download | - View final version: A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination (PDF, 2.0 MiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1002/cti2.1380 |
|---|
| Author | Search for: Colwill, KarenORCID identifier: https://orcid.org/0000-0002-8979-1659; Search for: Galipeau, Yannick; Search for: Stuible, Matthew1; Search for: Gervais, Christian1; Search for: Arnold, Corey; Search for: Rathod, Bhavisha; Search for: Abe, Kento T.; Search for: Wang, Jenny H.; Search for: Pasculescu, Adrian; Search for: Maltseva, Mariam; Search for: Rocheleau, Lynda; Search for: Pelchat, Martin; Search for: Fazel‐Zarandi, Mahya; Search for: Iskilova, Mariam; Search for: Barrios‐Rodiles, Miriam; Search for: Bennett, Linda; Search for: Yau, Kevin; Search for: Cholette, François; Search for: Mesa, Christine; Search for: Li, Angel X.; Search for: Paterson, Aimee; Search for: Hladunewich, Michelle A.; Search for: Goodwin, Pamela J.; Search for: Wrana, Jeffrey L.; Search for: Drews, Steven J.; Search for: Mubareka, Samira; Search for: McGeer, Allison J.; Search for: Kim, John; Search for: Langlois, Marc‐AndréORCID identifier: https://orcid.org/0000-0003-4652-3029; Search for: Gingras, Anne‐ClaudeORCID identifier: https://orcid.org/0000-0002-6090-4437; Search for: Durocher, Yves1ORCID identifier: https://orcid.org/0000-0002-2268-4111 |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Funder | Search for: Genome Canada; Search for: Ontario Genomics; Search for: Canada Foundation for Innovation; Search for: Royal Bank of Canada; Search for: Canadian Institutes of Health Research; Search for: Public Health Agency of Canada; Search for: Ontario Ministry of Research, Innovation and Science; Search for: National Research Council Canada; Search for: Krembil Foundation |
|---|
| Format | Text, Article |
|---|
| Subject | antibody detection; antibody neutralisation; assaydevelopment and standardisation; high-throughput screening; SARS-CoV-2 |
|---|
| Abstract | Objectives: Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.
Methods: We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD) and nucleocapsid (N). We automated a surrogate neutralisation (sn)ELISA that measures inhibition of ACE2-spike or -RBD interactions by antibodies. The assays were calibrated to a World Health Organization reference standard.
Results: Our single-point IgG-based ELISAs accurately distinguished non-infected and infected individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present detailed protocols for serum/plasma or dried blood spots analysis performed manually and on automated platforms. The snELISA can be performed automatically at single points, increasing its scalability.
Conclusions: Measuring antibodies to three viral antigens and identify neutralising antibodies capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to enable scaling up of standardised serological assays, permitting inter-laboratory data comparison and aggregation. |
|---|
| Publication date | 2022-03-23 |
|---|
| Publisher | Wiley |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 6beb58c9-0acf-4a2a-820f-9099fe0c80e8 |
|---|
| Record created | 2023-12-21 |
|---|
| Record modified | 2023-12-21 |
|---|
